TC Medical(SH:600763) Sou Hu Cai Jing·2025-12-23 12:31Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price, with significant net outflows from major and retail investors, while the company showed modest revenue and profit growth in its recent financial report [1][2]. Financial Performance - For the first three quarters of 2025, Tongce Medical achieved a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year [2]. - The net profit attributable to shareholders reached 514 million yuan, reflecting a year-on-year growth of 3.16% [2]. - The company's net profit excluding non-recurring items was 509 million yuan, up 3.09% year-on-year [2]. - In Q3 2025, the company reported a single-quarter main revenue of 842 million yuan, a 2.34% increase year-on-year [2]. - The single-quarter net profit attributable to shareholders was 192 million yuan, up 2.31% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was also 192 million yuan, reflecting a 1.85% year-on-year increase [2]. - The company's debt ratio stood at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan [2]. - The gross profit margin was reported at 41.69% [2]. Market Activity - As of December 23, 2025, Tongce Medical's stock closed at 40.68 yuan, down 0.83%, with a turnover rate of 0.68% and a trading volume of 30,500 hands, amounting to a transaction value of 124 million yuan [1]. - On December 23, the net outflow of major funds was 14.64 million yuan, accounting for 11.77% of the total transaction value, while retail investors saw a net inflow of 23.13 million yuan, representing 18.59% of the total transaction value [1].